Skip to main content

Odour-GPCRs based technology for detection and stratification of cancer: Prostate Cancer Smell Print as first vertical market

Objective

PCSP project is born out of the unique expertise developed after years of R&D at Canvax Biotech, and aims at transferring a technology to cover an unmet clinical need, accurate diagnosis of prostate cancer (PCa). Canvax owns a unique set of patented technologies: i) high expression of olfactory receptors (oGPCRs) in heterologous cells, ii) coupling to a signalling cascade and iii) readable fluorescent assays to quantify oGPCR activation. Canvax is producing an array of cells expressing oGPCRs that could be used to detect several types of cancer, including PCa, by detecting cancer-associated volatile organic compounds in urine. The technology is currently being tested in a PCa clinical trial. PCa detection has been widely carried out using the prostate specific antigen test. However, its low accuracy resulted in a high percentage of false positives and a still appreciable amount of false negatives. Several recent studies showed that trained dogs could detect PCa from urine samples with the higher accuracy. However, the use of dogs in clinic is difficult and non-scalable. Canvax PCSP test resembles a dog nose that pretends to be a universal screening method for PCa-type discrimination identifying, in simple urine test, patients in need of further, more invasive diagnostic procedures with higher accuracy than current standard of care, saving stress, anxiety and unnecessary risky procedures. The easy use and low cost of this technology makes it ideal for broad adoption. Different scenarios have been described for market penetration and would be subject of the feasibility study during phase I: Smell print definition, regulatory and market permits acquisition, clinical trial design, identification of best-selling points, EU extension and financial costs will be analysed. The appropriate measures will be applied during phase II, together with prototype validation in a large clinical trial to gain recognition within the physicians, and initial exploitation of the technology

Field of science

  • /social sciences/sociology/social issues/social inequality
  • /engineering and technology/medical engineering/medical laboratory technology/laboratory samples analysis
  • /natural sciences/computer and information sciences/data science/data analysis
  • /medical and health sciences/health sciences/public and environmental health
  • /agricultural sciences/animal and dairy science/pets
  • /natural sciences/chemical sciences/organic chemistry/volatile organic compounds
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug
  • /medical and health sciences/clinical medicine/cancer/prostate cancer
  • /social sciences/economics and business/business and management/commerce

Call for proposal

H2020-SMEINST-1-2014
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

CANVAX BIOTECH SL
Address
Polig Tecnocordoba Cl 14 E Parc 47 Planta 2
14014 Cordoba
Spain
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000